AgomAb Therapeutics (NASDAQ:AGMB) Raised to “Hold” at Wall Street Zen

AgomAb Therapeutics (NASDAQ:AGMB) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities analysts have also recently weighed in on the company. Piper Sandler began coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Stock Performance

NASDAQ:AGMB opened at $12.17 on Friday. AgomAb Therapeutics has a twelve month low of $8.75 and a twelve month high of $17.82. The company has a 50-day moving average of $13.33 and a 200-day moving average of $12.34.

AgomAb Therapeutics (NASDAQ:AGMB) last released its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Analysts forecast that AgomAb Therapeutics will post -1.76 earnings per share for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.

AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.